Endothelial ERK signaling controls lymphatic fate specification
about
Development of the mammalian lymphatic vasculatureLymphatic fate specification: an ERK-controlled transcriptional programEvidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunctionLymphatic regulator PROX1 determines Schlemm's canal integrity and identityIQGAP1 Mediates Hcp1-Promoted Escherichia coli Meningitis by Stimulating the MAPK Pathway.Apelin promotes lymphangiogenesis and lymph node metastasis.Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development.AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.mafba is a downstream transcriptional effector of Vegfc signaling essential for embryonic lymphangiogenesis in zebrafish.Choose your destiny: Make a cell fate decision with COUP-TFII.Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3.Endothelial RAF1/ERK activation regulates arterial morphogenesis.Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivationBMP-9 balances endothelial cell fate.Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.AIP1 mediates vascular endothelial cell growth factor receptor-3-dependent angiogenic and lymphangiogenic responses.Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period.Lymphatic vessel abnormalities arising from disorders of Ras signal transduction.Molecular and cellular mechanisms of lymphatic vascular maturation.Endothelial Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 Is Critical for Lymphatic Vascular Development and FunctionVascular heterogeneity and specialization in development and disease.Tissue factor pathway inhibitor-2 induced hepatocellular carcinoma cell differentiation.A Mathematical Model of Lymphangiogenesis in a Zebrafish Embryo.Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Vegfc acts through ERK to induce sprouting and differentiation of trunk lymphatic progenitors.Physiology. Lymphatics are in my veins.Lymphatic fate determination: playing RAF with ERK.Lymphatic vessels arise from specialized angioblasts within a venous niche.Organ-specific lymphatic vasculature: From development to pathophysiology.Lymphatic Endothelial Cell Plasticity in Development and Disease.All TIEd up: mechanisms of Schlemm's canal maintenance.New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
P2860
Q26852649-7746D5D2-1C5C-415B-B2A5-036D72A48182Q27005981-2A6C5417-CDFC-4038-9C55-854D6F181077Q27329602-7BC07A05-EF4C-4212-B390-74673E44471BQ28244698-1E9B7F10-96F3-4C20-B578-0E0E3E8B8E71Q33575987-2F87606E-BEB7-4C91-914B-80FCD13D77E8Q34100995-4684AB57-1D5C-4F3E-BB0A-3757F5A064ADQ34199625-FE142A88-F023-4638-8EF0-65491C0C28AAQ35196528-F4C25A0F-C995-4052-B72D-8CA043D2055AQ35952739-BC3FEBEC-7217-4FDB-8119-B22602F08A16Q36494101-7AB5885D-76FF-40BB-9B9F-DE2A97D58004Q36799205-8EE380D2-414A-4BB5-A7EB-8779EC4F9100Q36833572-AEC9378A-205E-4135-8CB0-FC0814E10DC9Q37042262-748949D0-EDDF-48EA-BAB9-6E370DEABA7BQ37340878-CAE155CE-9E15-4677-A72E-39EBCB0EA867Q37583522-FB778DAB-AC9F-49B0-A45D-0B49D96A60C9Q37634336-4D4AB553-98B5-46FB-9786-1B6E6F5974A3Q37672657-03157F47-9290-40CC-A471-BD5031A7BA84Q38158991-D1B2292B-D8DD-42AD-B264-D2BC7067C383Q38220152-E6DE5532-8D30-47E3-836C-345763096877Q38780686-06DFBF13-C2B3-4328-9448-32FC21EECB03Q39326100-B1C98D34-E826-4377-BD82-AF2E66574FE2Q40277662-07725CC4-0D17-4AF4-B175-A312C70ADF9EQ40958024-2C268324-570F-4801-A7C7-A3385DFE0C33Q41384256-8CFF14E5-FADE-4B0F-9E25-BA6F2DF98F42Q41970819-28B1039C-E436-46DF-A871-F86C28547FD6Q42377401-5F454A5A-4A8F-45A4-8B19-31D715BA4A82Q43025992-1938257C-2907-41A1-9E23-EA7D670087BEQ43138421-D8655F40-2625-4029-86C7-66C278585303Q47074052-555F935A-40D6-4577-A918-BC17129C7ABEQ47248578-CA40F1D7-1F08-4161-8024-19141364BA6EQ47817975-00879653-6195-4629-9A80-011301C93F3BQ50047944-C5C96953-FEA0-4E92-B261-631398816C17Q50648148-02565323-E3AD-4BC8-A4FC-0E4A70C5E832
P2860
Endothelial ERK signaling controls lymphatic fate specification
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Endothelial ERK signaling controls lymphatic fate specification
@ast
Endothelial ERK signaling controls lymphatic fate specification
@en
type
label
Endothelial ERK signaling controls lymphatic fate specification
@ast
Endothelial ERK signaling controls lymphatic fate specification
@en
prefLabel
Endothelial ERK signaling controls lymphatic fate specification
@ast
Endothelial ERK signaling controls lymphatic fate specification
@en
P2093
P2860
P356
P1476
Endothelial ERK signaling controls lymphatic fate specification
@en
P2093
Anne Eichmann
Deepak Atri
Michael Simons
P2860
P304
P356
10.1172/JCI63034
P407
P577
2013-02-08T00:00:00Z